Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
20 févr. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
28 janv. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
23 janv. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Provides Corporate and Product Pipeline Update
09 janv. 2020 07h30 HE
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) --...
Otonomy to Participate in Two Upcoming Investor Conferences
26 nov. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
05 nov. 2019 16h13 HE
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration...
Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update
29 oct. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
01 oct. 2019 07h30 HE
|
Otonomy, Inc.
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical...
Otonomy to Present at the Cantor Global Healthcare Conference
26 sept. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
17 sept. 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...